These experiments provided important information for the FDA to approve a Phase I Clinical Trial of delivery of MnSOD-PL twice weekly in patients with unresectable Stage IIIA/B non-small cell carcinoma or esophageal radioprotection [33]. The gene discussed is SOD2; the disease is non-small cell lung carcinoma.